SCHEMBL1354948

SCHEMBL1354948

CCCCCNS(=O)(=O)c1cc2ccccc2[nH]1

nearest known ligand 0.55

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 15/20 0.55
CA2 P00918 1/20 0.49
DRD2 P14416 1/20 0.48
DRD3 P35462 1/20 0.48
RECQL P46063 1/20 0.48
CA12 O43570 1/20 0.46
CA9 Q16790 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8983658 0.84 CNR1 (0.56) CNR1CA2
SCHEMBL6918547 0.84 CNR1 (0.62) CNR1CA2
SCHEMBL1039684 0.78 CA2 (0.53) CNR1CA2DRD2DRD3
SCHEMBL27751374 0.77 VCP (0.47) CA2RECQLCA12CA9
SCHEMBL7599250 0.76 CNR1 (0.44) CNR1
SCHEMBL4238494 0.76 CA2 (0.61) CNR1CA2
SCHEMBL27699542 0.75 POLB (0.48) CNR1CA2RECQLCA12CA9
SCHEMBL8799150 0.74 CNR1 (0.61) CNR1CA2
SCHEMBL11176535 0.74 L3MBTL1 (0.54) RECQLCA12CA9
SCHEMBL19928719 0.74 CA2 (0.58) CNR1CA2DRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318725-B2 Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands SUVEN LIFE SCIENCES LIMITED (IN) 2012-11-27 US disclosed
US-8318725-B2 Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands SUVEN LIFE SCIENCES LIMITED (IN) 2012-11-27 US disclosed
US-8318725-B2 Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands SUVEN LIFE SCIENCES LIMITED (IN) 2012-11-27 US disclosed
US-20110281849-A1 Aryl Indolyl Sulfonamide Compounds and Their Use as 5-HT6 Ligands SUVEN LIFE SCIENCES LIMITED (IN) 2011-11-17 US disclosed
US-20110281849-A1 Aryl Indolyl Sulfonamide Compounds and Their Use as 5-HT6 Ligands SUVEN LIFE SCIENCES LIMITED (IN) 2011-11-17 US disclosed
US-20110281849-A1 Aryl Indolyl Sulfonamide Compounds and Their Use as 5-HT6 Ligands SUVEN LIFE SCIENCES LIMITED (IN) 2011-11-17 US disclosed
WO-2010032257-A1 ARYL INDOLYL SULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2010-03-25 WO disclosed
WO-2010032257-A1 ARYL INDOLYL SULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2010-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281849-A1 Aryl Indolyl Sulfonamide Compounds and Their Use as 5-HT6 Ligands HTR6, HTR1A, HTR2C CNR1 152/4885CA2 3142/4885DRD2 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.